SPOTLIGHT -
Whatever the final outcome of the legal battle that has been going on between Nidek Co. and VISX Inc. for nearly 4 years, it is clear that those on the sidelines want such a contest never again to create such a burden for ophthalmologists.
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
EyePod: Modifier Gene Therapy: What is it?
Patients with dry eye suffer from worse sleep quality
Ophthalmic industry veteran Erin Schallhorn Powers joins Holland Foundation for Sight Restoration Board of Directors